Retatrutide phase 2 obesity results: the triple agonist explained
Research & educational use only. This content is not medical advice. Consult a qualified healthcare professional before using any peptide compound.
Retatrutide is an investigational triple agonist hitting the GIP, GLP-1, and glucagon receptors at once. The phase 2 obesity results reported some of the largest mean weight reductions seen for an incretin-based therapy, which is why it is getting so much attention ahead of phase 3.
Worth being precise: this is still investigational, not approved, and phase 2 results do not always hold up at scale. The glucagon-receptor component is the interesting differentiator versus the GLP-1 and GIP/GLP-1 drugs already on the market.
12